Your browser doesn't support javascript.
loading
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexander; Kaiser, Florian; Al-Batran, Salah-Edin; Heintges, Tobias; Lerchenmüller, Christoph; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Moehler, Markus; Scheithauer, Werner; Held, Swantje; Miller-Phillips, Lisa; Modest, Dominik Paul; Jung, Andreas; Kirchner, Thomas; Stintzing, Sebastian.
Afiliación
  • Heinemann V; Department of Medicine III, University Hospital, Ludwig Maximilian University (LMU), Munich, Germany. Volker.heinemann@med.uni-muenchen.de.
  • von Weikersthal LF; Gesundheitszentrum St. Marien, Amberg, Germany.
  • Decker T; Onkologie Ravensburg, Ravensburg, Germany.
  • Kiani A; Klinik Herzoghöhe, Bayreuth, Germany.
  • Kaiser F; Oncological Practice, Landshut, Germany.
  • Al-Batran SE; Institute of Clinical Cancer Research at Krankenhaus Nordwest University Cancer Center, Frankfurt, Germany.
  • Heintges T; Department of Medicine II, Städtische Kliniken Neuss, Neuss, Germany.
  • Lerchenmüller C; Oncological Practice, Münster, Germany.
  • Kahl C; Department of Haematology and Oncology, Städtisches Klinikum Magdeburg, Magdeburg, Germany.
  • Seipelt G; Oncological Practice, Bad Soden, Germany.
  • Kullmann F; Department of Medicine I, Klinikum Weiden, Weiden, Germany.
  • Moehler M; Department of Medicine II, University Hospital, Johannes Gutenberg University Mainz, Mainz, Germany.
  • Scheithauer W; Department of Internal Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Held S; ClinAssess GmbH, Leverkusen, Germany.
  • Miller-Phillips L; Department of Medicine III, University Hospital, Ludwig Maximilian University (LMU), Munich, Germany.
  • Modest DP; Department of Medicine III, University Hospital, Ludwig Maximilian University (LMU), Munich, Germany.
  • Jung A; Institute of Pathology, University of Munich, Munich, Germany.
  • Kirchner T; Institute of Pathology, University of Munich, Munich, Germany.
  • Stintzing S; Division of Hematology, Oncology, and Tumor Immunology (CCM), Department of Medicine, Charité Universitaetsmedizin Berlin, Berlin, Germany.
Br J Cancer ; 124(3): 587-594, 2021 02.
Article en En | MEDLINE | ID: mdl-33154570
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Camptotecina / Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab / Cetuximab Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Br J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Camptotecina / Neoplasias Colorrectales / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab / Cetuximab Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Adult / Aged / Humans / Middle aged Idioma: En Revista: Br J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Alemania